News of the company

Master class "Respiratory diseases during the pandemic COVID-19: differential diagnosis and treatment" within the All-Ukrainian Professional Respiratory School in Odessa

On April 23, 2021 a master class "Respiratory diseases during the pandemic COVID-19: differential diagnosis and treatment" was held in the online format within the All-Ukrainian professional respiratory school in Odessa

Leading experts in the field of allergology, pulmonology and otolaryngology have presented their reports on the diagnosis and treatment of diseases of the respiratory tract and ENT organs during the pandemic COVID-19.

Among the many reports presented as part of the master class, the conference participants were particularly interested in the report "Combined drugs – new opportunities in the treatment of allergic pathology” presented by of Gonta Irina Anatoliyivna, Ph.D., Assistant of the Chair of Internal Medicine with the Course of Cardiac Surgery of ONMU.

In her report Mrs Irina has emphasized that the most common allergic diseases are allergic rhinitis and bronchial asthma, which significantly worsen the quality of life of patients.

Clinical manifestations of histamine and leukotrienes being the main mediators of allergic inflammation are nasal congestion, rhinorrhoea, increased vascular permeability, redness of the skin and bronchospasm. All of the above symptoms often cause disorders, such as poor sleep, memory and concentration loss, reduced daily activity and even may cause bronchial asthma in the future.

According to the protocol for the treatment of allergic rhinitis, approved by the Ministry of Health of Ukraine, the therapy involves the use of drugs, such as H1-histamine receptor blockers and leukotriene receptor blockers.

As a rule, it is advisable to prescribe combination drugs containing levocetirizine and montelukast for patients with severe manifestations of allergic pathology. According to various studies published, the use of two drugs, such as levocetirizine and montelukast is more effective than monotherapy.

Recently, a new drug appeared on the Ukrainian market. This is Allerginol Plus, which includes a fixed combination of two components – levocetirizine – an antagonist of H1 histamine receptors and montelukast – an inhibitor of leukotriene receptors.

Allerginol Plus is recommended for patients to reduce the symptoms associated with seasonal and perennial allergic rhinitis, and rhinitis in patients with bronchial asthma as well. Allerginol Plus is approved for use after consulting your doctor. Adults and children over 15 years of age should take 1 tablet once a day in the evening, regardless of food intake. The course of treatment is 14 days *

Allerginol Plus is a double power against allergies!

* For more details see the instructions for medical use of the medicinal product Allerginol Plus. Registration certificate No.: UA/14440/01/01